FDA Grants De Novo Marketing Authorization for
Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States Diabetic Kidney Disease is the Leading Cause of...
Source: globenewswire.com
📰 Prognostic Test News
Prognostic Test News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Prognostic Test. Real-time updates on events, politics, business and more.
Renalytix test gets US FDA marketing authorisation
Renalytix announced on Friday that the US Food and Drug Administration (FDA) had granted De Novo marketing authorisation for its ‘KidneyIntelX.dkd’ prognostic test.
Source: sharecast.com